Get the Stockscreener App
3.12
8.33%
0.24
After Hours:
3.07
-0.05
-1.60%
Editas Medicine Inc stock is traded at $3.12, with a volume of 2.14M.
It is up +8.33% in the last 24 hours and down -7.69% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$2.88
Open:
$2.86
24h Volume:
2.14M
Relative Volume:
1.12
Market Cap:
$256.31M
Revenue:
$78.12M
Net Income/Loss:
$-153.22M
P/E Ratio:
-1.0541
EPS:
-2.96
Net Cash Flow:
$-136.90M
1W Performance:
+0.32%
1M Performance:
-7.69%
6M Performance:
-44.97%
1Y Performance:
-62.45%
1-Day Range:
$2.79
$3.17
1-Week Range:
$2.70
$3.17
52-Week Range:
$2.70
$11.69
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com
Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com
Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - Yahoo Finance Australia
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Barclays - MarketBeat
Editas Medicine (NASDAQ:EDIT) Announces Quarterly Earnings Results - MarketBeat
Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN
Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada
Editas Medicine Reports Q3 2024 Results and Developments - TipRanks
Editas downgraded to market perform by Raymond James - MSN
Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha
Editas Medicine (NASDAQ:EDIT) Stock Rating Lowered by Raymond James - MarketBeat
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com
Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Editas: Q3 Earnings Snapshot - The Washington Post
Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times
Editas Medicine stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia
Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - Yahoo Finance
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat
Editas’ new gene-editing strategy for SCD shows promise in mice - Sickle Cell Disease News
In vivo editing data advances lift hopes for better access - BioCentury
FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat
Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline - Yahoo Finance
Petri Dish: GSK partners with BU; Be Biopharma enters clinic - The Business Journals
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down - Yahoo Finance
Evercore ISI Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00 - MarketBeat
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts - Benzinga
Editas Medicine achieves in vivo preclinical proof of concept of HSPC editing - BioWorld Online
Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo - StreetInsider.com
Editas advances gene editing treatment for blood disorders By Investing.com - Investing.com Australia
Editas advances gene editing treatment for blood disorders - Investing.com India
Chardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $12.00 - MarketBeat
Possible Signal As Editas Medicine Insiders Sell US$1.2m In Stock - Simply Wall St
Baird cuts Editas Medicine target to $10 from $18 By Investing.com - Investing.com UK
Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D - MedCity News
Editas, changing course again, looks to partner lead CRISPR therapy - BioPharma Dive
Editas and Genevant team up to develop gene editing therapies - Pharmaceutical Technology
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Finance
Editas stock slips on plans for gene editing drug (EDIT:NASDAQ) - Seeking Alpha
Editas Medicine Announces Progress Towards 2024 Goals, - GlobeNewswire
Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept - Marketscreener.com
Editas Medicine (EDIT) Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update - StreetInsider.com
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update - StockTitan
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics - GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept - The Manila Times
Editas Medicine to Host Strategic Update Webinar to Detail - GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, ... - The Bakersfield Californian
State Street Corp's Strategic Reduction in Editas Medicine Inc H - GuruFocus.com
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):